shutterstock_1106850689_piotr_swat

Piotr Swat / Shutterstock.com

19 May 2022Sarah Speight

NIH COVID-19 deal broadens access for poorer nations

The Medicines Patent Pool (MPP) and World Health Organization’s (WHO) COVID-19 Technology Access Pool (C-TAP) have signed a deal aiming to open up new technologies to people living in poorer countries.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

More on this story

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB